Ji Yan Biomedical and Taipei Medical University Expand Academic Collaboration to Explore Gamma Delta T Cell Research in Liver Cancer

February 2025 — Taipei

Ji Yan Biomedical today announced the expansion of its research collaboration with Taipei Medical University (TMU) to investigate the application of gamma delta T cells (γδT) in hepatocellular carcinoma (HCC), the most common form of liver cancer.

This targeted academic-industry partnership focuses on evaluating the functional properties of γδT cells within liver cancer models and exploring their potential as a novel immunotherapeutic approach. The academic lead for the project is Dr. Tsung-I Hsu, Professor at TMU, whose research expertise includes oncology, neuroimmunology, and medical neuroscience.

This collaboration aligns with Ji Yan Biomedical’s broader strategy to leverage strong academic partnerships to deepen scientific understanding and advance preclinical development in high-need oncology areas.

“Liver cancer remains a major unmet need globally, and gamma delta T cells offer a promising avenue for new therapeutic strategies,” said Dr. Ethan Shen, CEO of Ji Yan Biomedical. “We are excited to work with TMU to explore how γδT cells may contribute to future innovations in immuno-oncology.”

The collaboration is governed by mutual confidentiality and intellectual property agreements, and all research activities will comply with applicable institutional, ethical, and regulatory standards.

About Ji Yan Biomedical

Ji Yan Biomedical is a biotechnology company dedicated to developing next-generation cell therapies and exosome-based innovations. The company partners with leading academic institutions to advance translational research and bring new therapeutic possibilities to areas of significant unmet medical need.